Loading organizations...
Based in Oklahoma City, Oklahoma, Cadenza Bio is a biotechnology company that develops non-steroidal, highly selective small-molecule compounds targeting Estrogen Receptor β to treat demyelinating and inflammatory diseases. The organization primarily focuses on therapeutics for multiple sclerosis, aiming to halt disease progression and promote remyelination, while also exploring preclinical applications for endometriosis. To support its preclinical drug development and advancement toward clinical trials, the enterprise secured $2.44 million in an oversubscribed Series Seed financing round. This funding was led by Plains Ventures, with additional participation from Cortado Ventures, Illinois Ventures, and the Oklahoma Life Science Fund. The company utilizes technology exclusively licensed from the University of Illinois Urbana-Champaign and the University of California, Riverside, which was previously supported by the National Multiple Sclerosis Society. Cadenza Bio was founded in 2022 by Carol Curtis and Elaine Hamm.
Cadenza Bio has raised $2.4M across 1 funding round.
Cadenza Bio has raised $2.4M in total across 1 funding round.
Cadenza Bio has raised $2.4M in total across 1 funding round.
Cadenza Bio's investors include Justin Wilson, Boyd Street Ventures, Cortado Ventures, Illinois Ventures, Oklahoma Life Science Fund.
Cadenza Bio has raised $2.4M across 1 funding round. Most recently, it raised $2.4M Seed in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 14, 2023 | $2.4M Seed | Justin Wilson | Boyd Street Ventures, Cortado Ventures, Illinois Ventures, Oklahoma Life Science Fund | Announced |
